Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Nitrendipine
- Accession Number
- DB01054 (APRD00421)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive. [PubChem]
- Structure
Structure for DB01054 (Nitrendipine)
- Synonyms
- 1,4-dihydro-2,6-Dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester
- BAY e 5009
- Bayotensin
- Baypress
- Bylotensin
- Deiten
- Nidrel
- Nitrendipino
- Nitrendipinum
- International/Other Brands
- Bayotensin / Baypress / Deiten / Nidrel / Nitrepin / Nitrezic
- Categories
- ACE Inhibitors and Calcium Channel Blockers
- Agents Acting on the Renin-Angiotensin System
- Antihypertensive Agents
- Calcium Channel Blockers
- Cardiovascular Agents
- Cardiovascular System
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 CYP3A7 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Dihydropyridines
- Hypotensive Agents
- Membrane Transport Modulators
- P-glycoprotein/ABCB1 Inhibitors
- Pyridines
- Vasodilator Agents
- UNII
- 9B627AW319
- CAS number
- 39562-70-4
- Weight
- Average: 360.3612
Monoisotopic: 360.132136382 - Chemical Formula
- C18H20N2O6
- InChI Key
- PVHUJELLJLJGLN-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3
- IUPAC Name
- 3-ethyl 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
- SMILES
- CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC
Pharmacology
- Indication
For the treatment of mild to moderate hypertension
- Structured Indications
- Not Available
- Pharmacodynamics
Nitrendipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nitrendipine is similar to other peripheral vasodilators. Nitrendipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
- Mechanism of action
By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nitrendipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
Target Actions Organism AVoltage-dependent L-type calcium channel subunit alpha-1C inhibitorHuman AVoltage-dependent calcium channel subunit alpha-2/delta-1 inhibitorHuman AVoltage-dependent L-type calcium channel subunit beta-2 inhibitorHuman AVoltage-dependent calcium channel gamma-1 subunit inhibitorHuman AVoltage-dependent L-type calcium channel subunit alpha-1D inhibitorHuman AVoltage-dependent L-type calcium channel subunit alpha-1S inhibitorHuman UVoltage-dependent calcium channel subunit alpha-2/delta-2 inhibitorHuman UVoltage-dependent T-type calcium channel subunit alpha-1H inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
> 99%
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
Pathway Category Nitrendipine Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 2-HYDROXY-1,4-NAPHTHOQUINONE The therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Nitrendipine. Experimental 2-mercaptobenzothiazole The therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Nitrendipine. Vet Approved 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nitrendipine. Experimental Acebutolol Nitrendipine may increase the hypotensive activities of Acebutolol. Approved, Investigational Acemetacin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Acemetacin. Approved, Experimental, Investigational Afatinib The serum concentration of Afatinib can be increased when it is combined with Nitrendipine. Approved Aldesleukin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin. Approved Alfuzosin Alfuzosin may increase the hypotensive activities of Nitrendipine. Approved, Investigational Aliskiren Nitrendipine may increase the hypotensive activities of Aliskiren. Approved, Investigational Alprenolol Alprenolol may increase the hypotensive activities of Nitrendipine. Approved, Withdrawn Ambrisentan Nitrendipine may increase the hypotensive activities of Ambrisentan. Approved, Investigational Amifostine Nitrendipine may increase the hypotensive activities of Amifostine. Approved, Investigational Amiloride The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amiloride. Approved Amiodarone The metabolism of Nitrendipine can be decreased when combined with Amiodarone. Approved, Investigational Amlodipine Amlodipine may increase the hypotensive activities of Nitrendipine. Approved Amobarbital The metabolism of Nitrendipine can be increased when combined with Amobarbital. Approved, Illicit Amorolfine The therapeutic efficacy of Amorolfine can be increased when used in combination with Nitrendipine. Approved, Investigational Amphetamine Amphetamine may increase the hypotensive activities of Nitrendipine. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitrendipine. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Nitrendipine is combined with Amyl Nitrite. Approved Anidulafungin The therapeutic efficacy of Anidulafungin can be increased when used in combination with Nitrendipine. Approved, Investigational Apalutamide The serum concentration of Nitrendipine can be decreased when it is combined with Apalutamide. Approved, Investigational Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Nitrendipine. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Apraclonidine. Approved Aprepitant The serum concentration of Nitrendipine can be increased when it is combined with Aprepitant. Approved, Investigational Aripiprazole Aripiprazole may increase the hypotensive activities of Nitrendipine. Approved, Investigational Arotinolol The risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Nitrendipine. Investigational Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nitrendipine. Approved, Investigational Artemether The therapeutic efficacy of Artemether can be increased when used in combination with Nitrendipine. Approved Asunaprevir The serum concentration of Asunaprevir can be increased when it is combined with Nitrendipine. Approved, Investigational, Withdrawn Atazanavir The metabolism of Nitrendipine can be decreased when combined with Atazanavir. Approved, Investigational Atenolol Atenolol may increase the hypotensive activities of Nitrendipine. Approved Atomoxetine The metabolism of Nitrendipine can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Atorvastatin. Approved Avanafil Avanafil may increase the antihypertensive activities of Nitrendipine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Azilsartan medoxomil. Approved, Investigational Bafilomycin A1 The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Nitrendipine. Experimental Barbexaclone Barbexaclone may increase the hypotensive activities of Nitrendipine. Experimental Barbital The metabolism of Nitrendipine can be increased when combined with Barbital. Illicit Barnidipine Nitrendipine may increase the antihypertensive activities of Barnidipine. Approved Benazepril Benazepril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Bendroflumethiazide Bendroflumethiazide may increase the hypotensive activities of Nitrendipine. Approved Benmoxin Benmoxin may increase the hypotensive activities of Nitrendipine. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be increased when used in combination with Nitrendipine. Approved, Investigational Bepridil Nitrendipine may increase the hypotensive activities of Bepridil. Approved, Withdrawn Betaxolol Betaxolol may increase the hypotensive activities of Nitrendipine. Approved, Investigational Bethanidine Bethanidine may increase the hypotensive activities of Nitrendipine. Approved Bietaserpine Bietaserpine may increase the hypotensive activities of Nitrendipine. Experimental Bifonazole The therapeutic efficacy of Bifonazole can be increased when used in combination with Nitrendipine. Approved, Investigational Bimatoprost Bimatoprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Bisoprolol Bisoprolol may increase the hypotensive activities of Nitrendipine. Approved Boceprevir The metabolism of Nitrendipine can be decreased when combined with Boceprevir. Approved, Withdrawn Bortezomib The metabolism of Nitrendipine can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Nitrendipine can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Nitrendipine. Approved BQ-123 Nitrendipine may increase the hypotensive activities of BQ-123. Investigational Brefeldin A The therapeutic efficacy of Brefeldin A can be increased when used in combination with Nitrendipine. Experimental Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Nitrendipine. Approved, Investigational Bretylium Nitrendipine may increase the hypotensive activities of Bretylium. Approved Brimonidine Brimonidine may increase the antihypertensive activities of Nitrendipine. Approved Brofaromine Brofaromine may increase the hypotensive activities of Nitrendipine. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nitrendipine. Approved, Investigational Bucindolol The risk or severity of hypotension can be increased when Bucindolol is combined with Nitrendipine. Investigational Bumetanide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Bumetanide. Approved Bunazosin The risk or severity of hypotension can be increased when Bunazosin is combined with Nitrendipine. Investigational Bupivacaine The risk or severity of adverse effects can be increased when Bupivacaine is combined with Nitrendipine. Approved, Investigational Bupranolol Nitrendipine may increase the hypotensive activities of Bupranolol. Approved Butenafine The therapeutic efficacy of Butenafine can be increased when used in combination with Nitrendipine. Approved Butoconazole The therapeutic efficacy of Butoconazole can be increased when used in combination with Nitrendipine. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Nitrendipine. Approved Cadralazine Cadralazine may increase the hypotensive activities of Nitrendipine. Experimental Cafedrine Nitrendipine may increase the hypotensive activities of Cafedrine. Investigational Calcium Acetate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Acetate. Approved, Investigational Calcium Chloride The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Chloride. Approved Calcium Citrate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Citrate. Approved Calcium glubionate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate. Approved Calcium Gluceptate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Gluceptate. Approved Calcium gluconate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium gluconate. Approved, Vet Approved Calcium lactate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate. Approved, Experimental, Investigational, Vet Approved Calcium lactate gluconate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium lactate gluconate. Experimental Calcium levulinate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium levulinate. Approved, Experimental Calcium pangamate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium pangamate. Experimental Calcium Phosphate The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Phosphate. Approved Canagliflozin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Canagliflozin. Approved Candesartan Nitrendipine may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Candesartan cilexetil may increase the hypotensive activities of Nitrendipine. Approved Candicidin The therapeutic efficacy of Candicidin can be increased when used in combination with Nitrendipine. Withdrawn Candoxatril Candoxatril may increase the hypotensive activities of Nitrendipine. Experimental Capric acid The therapeutic efficacy of Capric acid can be increased when used in combination with Nitrendipine. Experimental Captopril Nitrendipine may increase the hypotensive activities of Captopril. Approved Carbamazepine The metabolism of Nitrendipine can be increased when combined with Carbamazepine. Approved, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Nitrendipine. Approved, Investigational Caroxazone Caroxazone may increase the hypotensive activities of Nitrendipine. Withdrawn Carteolol Carteolol may increase the hypotensive activities of Nitrendipine. Approved Carvedilol Nitrendipine may increase the hypotensive activities of Carvedilol. Approved, Investigational Casein The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Casein. Approved Caspofungin The therapeutic efficacy of Caspofungin can be increased when used in combination with Nitrendipine. Approved Celiprolol Nitrendipine may increase the hypotensive activities of Celiprolol. Approved, Investigational Ceritinib The serum concentration of Nitrendipine can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Nitrendipine. Approved, Withdrawn Cerulenin The therapeutic efficacy of Cerulenin can be increased when used in combination with Nitrendipine. Approved Chlorothiazide Chlorothiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Chloroxine The therapeutic efficacy of Chloroxine can be increased when used in combination with Nitrendipine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nitrendipine. Approved, Investigational, Vet Approved Chlorthalidone Chlorthalidone may increase the hypotensive activities of Nitrendipine. Approved Cicletanine Nitrendipine may increase the hypotensive activities of Cicletanine. Investigational Ciclopirox The therapeutic efficacy of Ciclopirox can be increased when used in combination with Nitrendipine. Approved, Investigational Cilazapril Nitrendipine may increase the hypotensive activities of Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Nitrendipine. Approved, Investigational Cimetidine The serum concentration of Nitrendipine can be increased when it is combined with Cimetidine. Approved, Investigational Clarithromycin The metabolism of Nitrendipine can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Nitrendipine can be decreased when combined with Clemastine. Approved, Investigational Clevidipine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Clevidipine. Approved, Investigational Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Nitrendipine. Approved, Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Nitrendipine. Approved, Investigational, Vet Approved Clonidine Clonidine may increase the hypotensive activities of Nitrendipine. Approved Clopidogrel The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nitrendipine. Approved Cloranolol Nitrendipine may increase the hypotensive activities of Cloranolol. Experimental Clotrimazole The metabolism of Nitrendipine can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Nitrendipine. Approved Cobicistat The metabolism of Nitrendipine can be decreased when combined with Cobicistat. Approved Colchicine The serum concentration of Colchicine can be increased when it is combined with Nitrendipine. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Nitrendipine. Approved, Investigational Cordycepin The therapeutic efficacy of Cordycepin can be increased when used in combination with Nitrendipine. Investigational Crizotinib The metabolism of Nitrendipine can be decreased when combined with Crizotinib. Approved Cryptenamine Cryptenamine may increase the hypotensive activities of Nitrendipine. Approved Cyclopenthiazide Nitrendipine may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclosporine The metabolism of Nitrendipine can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyclothiazide Cyclothiazide may increase the hypotensive activities of Nitrendipine. Approved Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nitrendipine. Approved Dabrafenib The serum concentration of Nitrendipine can be decreased when it is combined with Dabrafenib. Approved, Investigational Dapagliflozin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dapagliflozin. Approved Darunavir The metabolism of Nitrendipine can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Nitrendipine can be increased when it is combined with Dasatinib. Approved, Investigational Debrisoquin Debrisoquin may increase the hypotensive activities of Nitrendipine. Approved, Investigational Deferasirox The serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox. Approved, Investigational Delapril Nitrendipine may increase the hypotensive activities of Delapril. Experimental Delavirdine The metabolism of Nitrendipine can be decreased when combined with Delavirdine. Approved Deserpidine Nitrendipine may increase the hypotensive activities of Deserpidine. Approved Desflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dexmedetomidine. Approved, Vet Approved Diazoxide Diazoxide may increase the hypotensive activities of Nitrendipine. Approved Dichlorophene The therapeutic efficacy of Dichlorophene can be increased when used in combination with Nitrendipine. Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Diclofenamide. Approved, Investigational Diethylnorspermine Nitrendipine may increase the hypotensive activities of Diethylnorspermine. Investigational Dihydralazine Dihydralazine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nitrendipine. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nitrendipine. Approved, Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nitrendipine. Experimental Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nitrendipine. Approved, Investigational Diltiazem The metabolism of Nitrendipine can be decreased when combined with Diltiazem. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dinutuximab. Approved, Investigational Dipyridamole The risk or severity of adverse effects can be increased when Nitrendipine is combined with Dipyridamole. Approved Dorzolamide Dorzolamide may increase the hypotensive activities of Nitrendipine. Approved Doxazosin Doxazosin may increase the hypotensive activities of Nitrendipine. Approved Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Nitrendipine. Approved, Investigational Doxycycline The metabolism of Nitrendipine can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Nitrendipine can be decreased when combined with Dronedarone. Approved Duloxetine Nitrendipine may increase the orthostatic hypotensive activities of Duloxetine. Approved Econazole The therapeutic efficacy of Econazole can be increased when used in combination with Nitrendipine. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Nitrendipine. Approved Efavirenz The serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz. Approved, Investigational Efinaconazole The therapeutic efficacy of Efinaconazole can be increased when used in combination with Nitrendipine. Approved Efonidipine Nitrendipine may increase the hypotensive activities of Efonidipine. Approved, Investigational Empagliflozin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Empagliflozin. Approved Enalapril Enalapril may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Enalaprilat Nitrendipine may increase the hypotensive activities of Enalaprilat. Approved Endralazine Endralazine may increase the hypotensive activities of Nitrendipine. Experimental Enzalutamide The serum concentration of Nitrendipine can be decreased when it is combined with Enzalutamide. Approved Epanolol Nitrendipine may increase the hypotensive activities of Epanolol. Experimental Eplerenone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Eplerenone. Approved Epoprostenol Nitrendipine may increase the hypotensive activities of Epoprostenol. Approved Eprosartan Eprosartan may increase the hypotensive activities of Nitrendipine. Approved Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Nitrendipine. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Nitrendipine. Approved Erythromycin The metabolism of Nitrendipine can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Esmolol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Esmolol. Approved Etacrynic acid The risk or severity of adverse effects can be increased when Nitrendipine is combined with Etacrynic acid. Approved, Investigational Everolimus The serum concentration of Everolimus can be increased when it is combined with Nitrendipine. Approved Felodipine Felodipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Fenoldopam Fenoldopam may increase the hypotensive activities of Nitrendipine. Approved Fenticonazole The therapeutic efficacy of Fenticonazole can be increased when used in combination with Nitrendipine. Experimental Ferulic acid Nitrendipine may increase the hypotensive activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Nitrendipine. Approved, Investigational Fluconazole The metabolism of Nitrendipine can be decreased when combined with Fluconazole. Approved, Investigational Flucytosine The therapeutic efficacy of Flucytosine can be increased when used in combination with Nitrendipine. Approved, Investigational Flutrimazole The therapeutic efficacy of Flutrimazole can be increased when used in combination with Nitrendipine. Experimental Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Nitrendipine. Approved Fluvoxamine The metabolism of Nitrendipine can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Nitrendipine can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Nitrendipine can be increased when it is combined with Fosaprepitant. Approved Fosinopril Fosinopril may increase the hypotensive activities of Nitrendipine. Approved Fosphenytoin The metabolism of Nitrendipine can be increased when combined with Fosphenytoin. Approved, Investigational Furazolidone Furazolidone may increase the hypotensive activities of Nitrendipine. Approved, Investigational, Vet Approved Furosemide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Furosemide. Approved, Vet Approved Fusidic Acid The serum concentration of Nitrendipine can be increased when it is combined with Fusidic Acid. Approved, Investigational Glyphosate The therapeutic efficacy of Glyphosate can be increased when used in combination with Nitrendipine. Experimental Griseofulvin The therapeutic efficacy of Griseofulvin can be increased when used in combination with Nitrendipine. Approved, Investigational, Vet Approved Guanabenz Guanabenz may increase the hypotensive activities of Nitrendipine. Approved, Investigational Guanadrel Guanadrel may increase the hypotensive activities of Nitrendipine. Approved Guanazodine Nitrendipine may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Nitrendipine may increase the hypotensive activities of Guanethidine. Approved Guanfacine Guanfacine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Guanoclor Nitrendipine may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Nitrendipine may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Nitrendipine may increase the hypotensive activities of Guanoxan. Experimental Hachimycin The therapeutic efficacy of Hachimycin can be increased when used in combination with Nitrendipine. Experimental Haloprogin The therapeutic efficacy of Haloprogin can be increased when used in combination with Nitrendipine. Approved, Withdrawn Halothane The risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine. Approved, Vet Approved Harmaline Harmaline may increase the hypotensive activities of Nitrendipine. Experimental Hexamethonium Nitrendipine may increase the hypotensive activities of Hexamethonium. Experimental Hexetidine The therapeutic efficacy of Hexetidine can be increased when used in combination with Nitrendipine. Approved, Investigational Hexobarbital The metabolism of Nitrendipine can be increased when combined with Hexobarbital. Approved Hydracarbazine Hydracarbazine may increase the hypotensive activities of Nitrendipine. Experimental Hydralazine Hydralazine may increase the hypotensive activities of Nitrendipine. Approved Hydrochlorothiazide Hydrochlorothiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Hydroflumethiazide Hydroflumethiazide may increase the hypotensive activities of Nitrendipine. Approved, Investigational Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Nitrendipine. Approved Idelalisib The metabolism of Nitrendipine can be decreased when combined with Idelalisib. Approved Iloprost The risk or severity of adverse effects can be increased when Iloprost is combined with Nitrendipine. Approved, Investigational Imatinib The metabolism of Nitrendipine can be decreased when combined with Imatinib. Approved Imidapril The risk or severity of adverse effects can be increased when Imidapril is combined with Nitrendipine. Investigational Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Nitrendipine. Approved Indapamide Indapamide may increase the hypotensive activities of Nitrendipine. Approved Indenolol Nitrendipine may increase the hypotensive activities of Indenolol. Withdrawn Indinavir The metabolism of Nitrendipine can be decreased when combined with Indinavir. Approved Indoramin Indoramin may increase the hypotensive activities of Nitrendipine. Withdrawn Iproclozide Iproclozide may increase the hypotensive activities of Nitrendipine. Withdrawn Iproniazid Iproniazid may increase the hypotensive activities of Nitrendipine. Withdrawn Irbesartan Irbesartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Isavuconazole The serum concentration of Nitrendipine can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Nitrendipine can be decreased when combined with Isavuconazonium. Approved, Investigational Isocarboxazid Isocarboxazid may increase the hypotensive activities of Nitrendipine. Approved Isoconazole The therapeutic efficacy of Isoconazole can be increased when used in combination with Nitrendipine. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Nitrendipine. Approved, Vet Approved Isosorbide Dinitrate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Mononitrate. Approved Isoxsuprine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Isoxsuprine. Approved, Withdrawn Isradipine The metabolism of Nitrendipine can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Nitrendipine can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Nitrendipine can be increased when it is combined with Ivacaftor. Approved Ketanserin Ketanserin may increase the hypotensive activities of Nitrendipine. Investigational Ketoconazole The metabolism of Nitrendipine can be decreased when combined with Ketoconazole. Approved, Investigational Labetalol Labetalol may increase the hypotensive activities of Nitrendipine. Approved Lacidipine Nitrendipine may increase the hypotensive activities of Lacidipine. Approved, Investigational Latanoprost Latanoprost may increase the hypotensive activities of Nitrendipine. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Nitrendipine. Approved Lercanidipine Lercanidipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nitrendipine. Approved, Investigational Levodopa Nitrendipine may increase the orthostatic hypotensive activities of Levodopa. Approved Levosimendan The risk or severity of adverse effects can be increased when Levosimendan is combined with Nitrendipine. Approved, Investigational Linsidomine Nitrendipine may increase the hypotensive activities of Linsidomine. Experimental Lisinopril Lisinopril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Nitrendipine. Approved, Investigational Lofexidine Nitrendipine may increase the hypotensive activities of Lofexidine. Approved, Investigational Lopinavir The metabolism of Nitrendipine can be decreased when combined with Lopinavir. Approved Lorpiprazole The serum concentration of Nitrendipine can be increased when it is combined with Lorpiprazole. Approved Losartan Losartan may increase the hypotensive activities of Nitrendipine. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Nitrendipine. Approved, Investigational Luliconazole The serum concentration of Nitrendipine can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Nitrendipine can be increased when combined with Lumacaftor. Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nitrendipine. Illicit, Investigational, Withdrawn Macitentan Nitrendipine may increase the hypotensive activities of Macitentan. Approved Magnesium hydroxide The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium oxide. Approved Magnesium salicylate The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium salicylate. Approved Magnesium sulfate The risk or severity of hypotension and neuromuscular blockade can be increased when Nitrendipine is combined with Magnesium sulfate. Approved, Investigational, Vet Approved Manidipine Nitrendipine may increase the hypotensive activities of Manidipine. Approved, Investigational Mannitol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Mannitol. Approved, Investigational Mebanazine Mebanazine may increase the hypotensive activities of Nitrendipine. Withdrawn Mecamylamine Mecamylamine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Mepartricin The therapeutic efficacy of Mepartricin can be increased when used in combination with Nitrendipine. Experimental Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Nitrendipine. Experimental Methazolamide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methazolamide. Approved Methohexital The metabolism of Nitrendipine can be increased when combined with Methohexital. Approved Methoserpidine Nitrendipine may increase the hypotensive activities of Methoserpidine. Experimental Methyclothiazide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Methyclothiazide. Approved Methyldopa Methyldopa may increase the hypotensive activities of Nitrendipine. Approved Methylene blue Methylene blue may increase the hypotensive activities of Nitrendipine. Approved, Investigational Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nitrendipine. Approved Methylphenidate Methylphenidate may decrease the antihypertensive activities of Nitrendipine. Approved, Investigational Methylphenobarbital The metabolism of Nitrendipine can be increased when combined with Methylphenobarbital. Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Nitrendipine. Approved Metipranolol Nitrendipine may increase the hypotensive activities of Metipranolol. Approved Metolazone Metolazone may increase the hypotensive activities of Nitrendipine. Approved Metoprolol Metoprolol may increase the hypotensive activities of Nitrendipine. Approved, Investigational Metyrosine Nitrendipine may increase the hypotensive activities of Metyrosine. Approved Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Nitrendipine. Experimental Mibefradil Nitrendipine may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Micafungin The therapeutic efficacy of Micafungin can be increased when used in combination with Nitrendipine. Approved, Investigational Miconazole The therapeutic efficacy of Miconazole can be increased when used in combination with Nitrendipine. Approved, Investigational, Vet Approved Mifepristone The serum concentration of Nitrendipine can be increased when it is combined with Mifepristone. Approved, Investigational Miltefosine The therapeutic efficacy of Miltefosine can be increased when used in combination with Nitrendipine. Approved, Investigational Minaprine Minaprine may increase the hypotensive activities of Nitrendipine. Approved Minoxidil Minoxidil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Mirodenafil Mirodenafil may increase the antihypertensive activities of Nitrendipine. Investigational Mitotane The serum concentration of Nitrendipine can be decreased when it is combined with Mitotane. Approved Moclobemide Moclobemide may increase the hypotensive activities of Nitrendipine. Approved, Investigational Moexipril Moexipril may increase the hypotensive activities of Nitrendipine. Approved Molsidomine Molsidomine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Monensin The therapeutic efficacy of Monensin can be increased when used in combination with Nitrendipine. Vet Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Nitrendipine. Approved, Investigational Moxonidine Moxonidine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Muzolimine Nitrendipine may increase the hypotensive activities of Muzolimine. Experimental Myxothiazol The therapeutic efficacy of Myxothiazol can be increased when used in combination with Nitrendipine. Experimental Nabilone The risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine. Approved, Investigational Nadolol Nitrendipine may increase the hypotensive activities of Nadolol. Approved Nafcillin The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Nafcillin. Approved, Investigational Naftifine The therapeutic efficacy of Naftifine can be increased when used in combination with Nitrendipine. Approved Naftopidil Nitrendipine may increase the hypotensive activities of Naftopidil. Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Nitrendipine. Approved Natamycin The therapeutic efficacy of Natamycin can be increased when used in combination with Nitrendipine. Approved Nebivolol Nitrendipine may increase the hypotensive activities of Nebivolol. Approved, Investigational Nefazodone The metabolism of Nitrendipine can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Nitrendipine can be decreased when combined with Nelfinavir. Approved Nesiritide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nesiritide. Approved, Investigational Netupitant The serum concentration of Nitrendipine can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Nitrendipine can be increased when combined with Nevirapine. Approved Nialamide Nialamide may increase the hypotensive activities of Nitrendipine. Withdrawn Nicardipine Nicardipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Nitrendipine. Approved, Investigational Nicorandil Nicorandil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nifedipine. Approved Nifuratel The therapeutic efficacy of Nifuratel can be increased when used in combination with Nitrendipine. Experimental Niguldipine Nitrendipine may increase the hypotensive activities of Niguldipine. Experimental Nikkomycin Z The therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Nitrendipine. Investigational Nilotinib The metabolism of Nitrendipine can be decreased when combined with Nilotinib. Approved, Investigational Nilvadipine Nitrendipine may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimodipine Nimodipine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Nitrendipine. Approved Nisoldipine Nisoldipine may increase the hypotensive activities of Nitrendipine. Approved Nitric Oxide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitric Oxide. Approved Nitroglycerin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitroglycerin. Approved, Investigational Nitroprusside Nitrendipine may increase the hypotensive activities of Nitroprusside. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Nitrendipine is combined with Nitrous acid. Approved, Investigational Nitroxoline The therapeutic efficacy of Nitroxoline can be increased when used in combination with Nitrendipine. Approved Nystatin The therapeutic efficacy of Nystatin can be increased when used in combination with Nitrendipine. Approved, Vet Approved Obinutuzumab Nitrendipine may increase the hypotensive activities of Obinutuzumab. Approved, Investigational Octamoxin Octamoxin may increase the hypotensive activities of Nitrendipine. Withdrawn Olaparib The metabolism of Nitrendipine can be decreased when combined with Olaparib. Approved Olmesartan Olmesartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Omapatrilat Omapatrilat may increase the hypotensive activities of Nitrendipine. Investigational Omoconazole The therapeutic efficacy of Omoconazole can be increased when used in combination with Nitrendipine. Experimental Osimertinib The serum concentration of Nitrendipine can be increased when it is combined with Osimertinib. Approved Oxiconazole The therapeutic efficacy of Oxiconazole can be increased when used in combination with Nitrendipine. Approved Oxprenolol Nitrendipine may increase the hypotensive activities of Oxprenolol. Approved Paclitaxel The risk or severity of adverse effects can be increased when Nitrendipine is combined with Paclitaxel. Approved, Vet Approved Pafuramidine The therapeutic efficacy of Pafuramidine can be increased when used in combination with Nitrendipine. Investigational Palbociclib The serum concentration of Nitrendipine can be increased when it is combined with Palbociclib. Approved, Investigational Papaverine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Papaverine. Approved, Investigational Pargyline Pargyline may increase the hypotensive activities of Nitrendipine. Approved Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Nitrendipine. Approved Penbutolol Nitrendipine may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentamidine The therapeutic efficacy of Pentamidine can be increased when used in combination with Nitrendipine. Approved, Investigational Pentobarbital The metabolism of Nitrendipine can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pentolinium Nitrendipine may increase the hypotensive activities of Pentolinium. Approved Pentoxifylline Pentoxifylline may increase the hypotensive activities of Nitrendipine. Approved, Investigational Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Nitrendipine. Approved, Investigational, Vet Approved, Withdrawn Perindopril Perindopril may increase the hypotensive activities of Nitrendipine. Approved Phenelzine Phenelzine may increase the hypotensive activities of Nitrendipine. Approved Pheniprazine Pheniprazine may increase the hypotensive activities of Nitrendipine. Withdrawn Phenobarbital The metabolism of Nitrendipine can be increased when combined with Phenobarbital. Approved, Investigational Phenoxybenzamine Phenoxybenzamine may increase the hypotensive activities of Nitrendipine. Approved Phenoxypropazine Phenoxypropazine may increase the hypotensive activities of Nitrendipine. Withdrawn Phentolamine Phentolamine may increase the hypotensive activities of Nitrendipine. Approved Phenytoin The metabolism of Nitrendipine can be increased when combined with Phenytoin. Approved, Vet Approved Pinacidil Pinacidil may increase the hypotensive activities of Nitrendipine. Approved Pindolol Pindolol may increase the hypotensive activities of Nitrendipine. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone. Approved, Investigational Pirlindole Pirlindole may increase the hypotensive activities of Nitrendipine. Approved Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Nitrendipine. Approved Pitolisant The serum concentration of Nitrendipine can be decreased when it is combined with Pitolisant. Approved, Investigational Pivhydrazine Pivhydrazine may increase the hypotensive activities of Nitrendipine. Withdrawn Platelet Activating Factor Nitrendipine may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide Nitrendipine may increase the hypotensive activities of Polythiazide. Approved Posaconazole The metabolism of Nitrendipine can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pramipexole The risk or severity of adverse effects can be increased when Nitrendipine is combined with Pramipexole. Approved, Investigational Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine. Approved Prazosin Prazosin may increase the hypotensive activities of Nitrendipine. Approved Primidone The metabolism of Nitrendipine can be increased when combined with Primidone. Approved, Vet Approved Procarbazine Procarbazine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Propofol. Approved, Investigational, Vet Approved Propranolol Propranolol may increase the hypotensive activities of Nitrendipine. Approved, Investigational Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Nitrendipine. Approved Pyrrolnitrin The therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Nitrendipine. Experimental Quetiapine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Quetiapine. Approved Quinapril Quinapril may increase the hypotensive activities of Nitrendipine. Approved, Investigational Quinine Quinine may increase the hypotensive activities of Nitrendipine. Approved Radicicol The therapeutic efficacy of Radicicol can be increased when used in combination with Nitrendipine. Experimental Ramipril Ramipril may increase the hypotensive activities of Nitrendipine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Nitrendipine. Approved, Investigational Rasagiline Rasagiline may increase the hypotensive activities of Nitrendipine. Approved Remifentanil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil. Approved Remikiren Remikiren may increase the hypotensive activities of Nitrendipine. Approved Rescinnamine Nitrendipine may increase the hypotensive activities of Rescinnamine. Approved Reserpine Reserpine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Rifabutin The metabolism of Nitrendipine can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Nitrendipine can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Nitrendipine can be increased when combined with Rifapentine. Approved, Investigational Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Nitrendipine. Approved, Investigational Rilmenidine Rilmenidine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Nitrendipine. Approved Riociguat Nitrendipine may increase the hypotensive activities of Riociguat. Approved Risperidone Nitrendipine may increase the hypotensive activities of Risperidone. Approved, Investigational Rituximab Nitrendipine may increase the hypotensive activities of Rituximab. Approved Ropinirole The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Ropivacaine. Approved Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Nitrendipine. Approved Rotigotine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Rotigotine. Approved Rucaparib The metabolism of Nitrendipine can be decreased when combined with Rucaparib. Approved, Investigational Sacubitril The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sacubitril. Approved Safrazine Safrazine may increase the hypotensive activities of Nitrendipine. Withdrawn Salicylhydroxamic Acid The therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Nitrendipine. Experimental Salicylic acid The therapeutic efficacy of Salicylic acid can be increased when used in combination with Nitrendipine. Approved, Investigational, Vet Approved Saprisartan Nitrendipine may increase the hypotensive activities of Saprisartan. Experimental Saquinavir The metabolism of Nitrendipine can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sarilumab. Approved, Investigational Secobarbital The metabolism of Nitrendipine can be increased when combined with Secobarbital. Approved, Vet Approved Selegiline Selegiline may increase the hypotensive activities of Nitrendipine. Approved, Investigational, Vet Approved Selexipag Nitrendipine may increase the hypotensive activities of Selexipag. Approved Sertaconazole The therapeutic efficacy of Sertaconazole can be increased when used in combination with Nitrendipine. Approved, Investigational Sevoflurane The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane. Approved, Vet Approved Sildenafil Sildenafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Nitrendipine. Approved Siltuximab The serum concentration of Nitrendipine can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Nitrendipine can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Nitrendipine. Approved Sinefungin The therapeutic efficacy of Sinefungin can be increased when used in combination with Nitrendipine. Experimental Sirolimus The therapeutic efficacy of Sirolimus can be increased when used in combination with Nitrendipine. Approved, Investigational Sitaxentan Nitrendipine may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Sotalol The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sotalol. Approved Spirapril Nitrendipine may increase the hypotensive activities of Spirapril. Approved Spironolactone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Spironolactone. Approved St. John's Wort The serum concentration of Nitrendipine can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Nitrendipine can be increased when it is combined with Stiripentol. Approved Streptokinase The risk or severity of adverse effects can be increased when Nitrendipine is combined with Streptokinase. Approved, Investigational Sufentanil The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil. Approved, Investigational Sulconazole The therapeutic efficacy of Sulconazole can be increased when used in combination with Nitrendipine. Approved Sulfisoxazole The metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Tadalafil Tadalafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Talinolol Nitrendipine may increase the hypotensive activities of Talinolol. Investigational Tamsulosin The risk or severity of hypotension can be increased when Tamsulosin is combined with Nitrendipine. Approved, Investigational Tavaborole The therapeutic efficacy of Tavaborole can be increased when used in combination with Nitrendipine. Approved, Investigational Telaprevir The metabolism of Nitrendipine can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Nitrendipine can be decreased when combined with Telithromycin. Approved Telmisartan Telmisartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Temocapril Nitrendipine may increase the hypotensive activities of Temocapril. Experimental, Investigational Terazosin The risk or severity of hypotension can be increased when Terazosin is combined with Nitrendipine. Approved Terbinafine The therapeutic efficacy of Terbinafine can be increased when used in combination with Nitrendipine. Approved, Investigational, Vet Approved Terconazole The therapeutic efficacy of Terconazole can be increased when used in combination with Nitrendipine. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Nitrendipine. Experimental Terlipressin Nitrendipine may increase the hypotensive activities of Terlipressin. Approved, Investigational Tetrahydropalmatine Nitrendipine may increase the hypotensive activities of Tetrahydropalmatine. Investigational Thalidomide The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thalidomide. Approved, Investigational, Withdrawn Theodrenaline Nitrendipine may increase the hypotensive activities of Theodrenaline. Investigational Thiamylal The metabolism of Nitrendipine can be increased when combined with Thiamylal. Approved, Vet Approved Thiopental The metabolism of Nitrendipine can be increased when combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Thioridazine. Approved, Withdrawn Thymol The therapeutic efficacy of Thymol can be increased when used in combination with Nitrendipine. Approved Tibolone Nitrendipine may increase the hypotensive activities of Tibolone. Approved, Investigational Ticlopidine The metabolism of Nitrendipine can be decreased when combined with Ticlopidine. Approved Ticrynafen Nitrendipine may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol Timolol may increase the hypotensive activities of Nitrendipine. Approved Tioconazole The therapeutic efficacy of Tioconazole can be increased when used in combination with Nitrendipine. Approved Tizanidine The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tizanidine. Approved, Investigational Tocilizumab The serum concentration of Nitrendipine can be decreased when it is combined with Tocilizumab. Approved Tolazoline Tolazoline may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tolcapone. Approved, Withdrawn Tolciclate The therapeutic efficacy of Tolciclate can be increased when used in combination with Nitrendipine. Experimental Tolnaftate The therapeutic efficacy of Tolnaftate can be increased when used in combination with Nitrendipine. Approved, Investigational, Vet Approved Tolonidine Nitrendipine may increase the hypotensive activities of Tolonidine. Experimental Toloxatone Toloxatone may increase the hypotensive activities of Nitrendipine. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Nitrendipine. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Nitrendipine. Approved, Investigational Torasemide Torasemide may increase the hypotensive activities of Nitrendipine. Approved Trandolapril Trandolapril may increase the hypotensive activities of Nitrendipine. Approved Tranylcypromine Tranylcypromine may increase the hypotensive activities of Nitrendipine. Approved, Investigational Travoprost Travoprost may increase the hypotensive activities of Nitrendipine. Approved Treprostinil Treprostinil may increase the hypotensive activities of Nitrendipine. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Nitrendipine is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene The risk or severity of adverse effects can be increased when Nitrendipine is combined with Triamterene. Approved Trichlormethiazide Trichlormethiazide may increase the hypotensive activities of Nitrendipine. Approved, Vet Approved Trimazosin Trimazosin may increase the hypotensive activities of Nitrendipine. Experimental Trimethaphan Trimethaphan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Trimetrexate The therapeutic efficacy of Trimetrexate can be increased when used in combination with Nitrendipine. Approved, Investigational Udenafil Udenafil may increase the antihypertensive activities of Nitrendipine. Approved, Investigational Unoprostone Nitrendipine may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Urapidil may increase the hypotensive activities of Nitrendipine. Investigational Ursodeoxycholic acid Ursodeoxycholic acid can cause a decrease in the absorption of Nitrendipine resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Valsartan Valsartan may increase the hypotensive activities of Nitrendipine. Approved, Investigational Vardenafil Vardenafil may increase the antihypertensive activities of Nitrendipine. Approved Vemurafenib The serum concentration of Nitrendipine can be decreased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Nitrendipine can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Nitrendipine can be decreased when combined with Verapamil. Approved Vincamine Nitrendipine may increase the hypotensive activities of Vincamine. Experimental Vincristine The excretion of Vincristine can be decreased when combined with Nitrendipine. Approved, Investigational Vinpocetine Nitrendipine may increase the hypotensive activities of Vinpocetine. Investigational Voriconazole The metabolism of Nitrendipine can be decreased when combined with Voriconazole. Approved, Investigational Xipamide Nitrendipine may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Nitrendipine may increase the hypotensive activities of Xylometazoline. Approved, Investigational Yohimbine Yohimbine may decrease the antihypertensive activities of Nitrendipine. Approved, Investigational, Vet Approved Ziprasidone The metabolism of Nitrendipine can be decreased when combined with Ziprasidone. Approved Zofenopril Nitrendipine may increase the hypotensive activities of Zofenopril. Experimental - Food Interactions
- Not Available
References
- Synthesis Reference
Wolfgang Schmidt, Bernhard Streuff, Manfred Winter, "Preparation of solid medicament formulation containing nitrendipine." U.S. Patent US4724141, issued April, 1980.
US4724141- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015187
- KEGG Drug
- D00629
- KEGG Compound
- C07713
- PubChem Compound
- 4507
- PubChem Substance
- 46508817
- ChemSpider
- 4351
- BindingDB
- 50012016
- ChEBI
- 7582
- ChEMBL
- CHEMBL475534
- Therapeutic Targets Database
- DAP001263
- PharmGKB
- PA146096020
- IUPHAR
- 2334
- Guide to Pharmacology
- GtP Drug Page
- Wikipedia
- Nitrendipine
- ATC Codes
- C08CA08 — Nitrendipine
- C08CA — Dihydropyridine derivatives
- C08C — SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
- C08 — CALCIUM CHANNEL BLOCKERS
- C — CARDIOVASCULAR SYSTEM
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Treatment High Blood Pressure (Hypertension) 1 4 Withdrawn Treatment Chronic Kidney Disease (CKD) / High Blood Pressure (Hypertension) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 156-160 °C Not Available water solubility Insoluble Not Available logP 2.88 MASUMATO,K ET AL. (1995) Caco2 permeability -4.77 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.0142 mg/mL ALOGPS logP 3.21 ALOGPS logP 2.17 ChemAxon logS -4.4 ALOGPS pKa (Strongest Basic) 5.43 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 110.45 Å2 ChemAxon Rotatable Bond Count 7 ChemAxon Refractivity 96.91 m3·mol-1 ChemAxon Polarizability 36.25 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9536 Blood Brain Barrier - 0.9549 Caco-2 permeable + 0.7853 P-glycoprotein substrate Substrate 0.5265 P-glycoprotein inhibitor I Inhibitor 0.8564 P-glycoprotein inhibitor II Inhibitor 0.8313 Renal organic cation transporter Non-inhibitor 0.8984 CYP450 2C9 substrate Non-substrate 0.8212 CYP450 2D6 substrate Non-substrate 0.8931 CYP450 3A4 substrate Substrate 0.7266 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Inhibitor 0.8949 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Inhibitor 0.8993 CYP450 3A4 inhibitor Inhibitor 0.8037 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.9247 Ames test Non AMES toxic 0.7334 Carcinogenicity Non-carcinogens 0.5186 Biodegradation Not ready biodegradable 0.9581 Rat acute toxicity 2.3810 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8131 hERG inhibition (predictor II) Non-inhibitor 0.9094
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-QFT , negative LC-MS/MS splash10-0ab9-2539000000-3d9a9111a145f234fc24 MS/MS Spectrum - , positive LC-MS/MS splash10-016r-0159000000-7b0ccf9fb639868092f0 LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-016r-0159000000-4e10a6643ba97ab23a0f
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Hydropyridines
- Direct Parent
- Dihydropyridinecarboxylic acids and derivatives
- Alternative Parents
- Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines show 6 more
- Substituents
- Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide show 23 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- C-nitro compound, ethyl ester, diester, dihydropyridine (CHEBI:7582)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1C
- Uniprot ID
- Q13936
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1C
- Molecular Weight
- 248974.1 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
- Gene Name
- CACNA2D1
- Uniprot ID
- P54289
- Uniprot Name
- Voltage-dependent calcium channel subunit alpha-2/delta-1
- Molecular Weight
- 124566.93 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
- Gene Name
- CACNB2
- Uniprot ID
- Q08289
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit beta-2
- Molecular Weight
- 73579.925 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- This protein is a subunit of the dihydropyridine (DHP) sensitive calcium channel. Plays a role in excitation-contraction coupling. The skeletal muscle DHP-sensitive Ca(2+) channel may function only...
- Gene Name
- CACNG1
- Uniprot ID
- Q06432
- Uniprot Name
- Voltage-dependent calcium channel gamma-1 subunit
- Molecular Weight
- 25028.105 Da
References
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity involved sa node cell action potential
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1D
- Uniprot ID
- Q01668
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1D
- Molecular Weight
- 245138.75 Da
References
- Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1S
- Uniprot ID
- Q13698
- Uniprot Name
- Voltage-dependent L-type calcium channel subunit alpha-1S
- Molecular Weight
- 212348.1 Da
References
- Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated calcium channel activity
- Specific Function
- The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
- Gene Name
- CACNA2D2
- Uniprot ID
- Q9NY47
- Uniprot Name
- Voltage-dependent calcium channel subunit alpha-2/delta-2
- Molecular Weight
- 129816.095 Da
References
- Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Scaffold protein binding
- Specific Function
- Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
- Gene Name
- CACNA1H
- Uniprot ID
- O95180
- Uniprot Name
- Voltage-dependent T-type calcium channel subunit alpha-1H
- Molecular Weight
- 259160.2 Da
References
- Perez-Reyes E, Van Deusen AL, Vitko I: Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. doi: 10.1124/jpet.108.145672. Epub 2008 Oct 30. [PubMed:18974361]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674]
- Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 02:07